$FBIO
Fortress Biotech, Inc. Stock $fbio

$fbio Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-Q Financial Statement

#000114420415029340 Filed on May 11, 2015

Income Statement

Concept	2015 Q1	2014 Q1
Revenue	$500.0K	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.490M	$2.100M
YoY Change	66.19%	-15.32%
% of Gross Profit
Research & Development	$1.642M	$4.487M
YoY Change	-63.41%	-24.89%
% of Gross Profit
Depreciation & Amortization	$6.000K	$5.000K
YoY Change	20.0%	66.67%
% of Gross Profit
Operating Expenses	$12.57M	$6.582M
YoY Change	90.99%	10.18%
Operating Profit	-$12.57M	-$6.582M
YoY Change	90.99%	-22.18%
Interest Expense	$331.0K	$966.0K
YoY Change	-65.73%	102.94%
% of Operating Profit
Other Income/Expense, Net	-$464.0K	-$788.0K
YoY Change	-41.12%
Pretax Income	-$12.54M	-$7.370M
YoY Change	70.15%	-16.82%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$12.06M	-$7.370M
YoY Change	63.58%	-16.8%
Net Earnings / Revenue	-2411.2%
Basic Earnings Per Share
Diluted Earnings Per Share	-$312.7K	-$205.3K
COMMON SHARES
Basic Shares Outstanding		44.09M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q1	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$72.88M	$80.00M
YoY Change	-8.9%	81.41%
Cash & Equivalents	$48.93M	$79.98M
Short-Term Investments	$23.95M
Other Short-Term Assets	$700.0K	$500.0K
YoY Change	40.0%	-50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$69.60M	$80.50M
YoY Change	-13.54%	78.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00	$69.00K
YoY Change	-100.0%	-31.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$250.0K	$250.0K
YoY Change	0.0%
Other Assets	$15.60M	$70.00K
YoY Change	22185.71%	-76.67%
Total Long-Term Assets	$20.90M	$14.40M
YoY Change	45.16%	3499.5%
TOTAL ASSETS
Total Short-Term Assets	$69.60M	$80.50M
Total Long-Term Assets	$20.90M	$14.40M
Total Assets	$90.50M	$94.90M
YoY Change	-4.64%	108.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$700.0K	$872.0K
YoY Change	-19.72%	24.57%
Accrued Expenses	$5.300M	$3.438M
YoY Change	54.16%	49.48%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00
YoY Change		-100.0%
Total Short-Term Liabilities	$5.900M	$4.335M
YoY Change	36.1%	-30.08%
LONG-TERM LIABILITIES
Long-Term Debt	$24.00M	$14.00M
YoY Change	71.43%	26.13%
Other Long-Term Liabilities	$300.0K	$1.066M
YoY Change	-71.86%	-28.93%
Total Long-Term Liabilities	$24.30M	$1.066M
YoY Change	2179.55%	-91.54%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.900M	$4.335M
Total Long-Term Liabilities	$24.30M	$1.066M
Total Liabilities	$30.30M	$19.41M
YoY Change	56.11%	3.8%
SHAREHOLDERS EQUITY
Retained Earnings		-$128.7M
YoY Change
Common Stock		$44.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$60.20M	$75.49M
YoY Change
Total Liabilities & Shareholders Equity	$90.50M	$94.90M
YoY Change	-4.64%	108.57%

Cashflow Statement

Concept	2015 Q1	2014 Q1
OPERATING ACTIVITIES
Net Income	-$12.06M	-$7.370M
YoY Change	63.58%	-16.8%
Depreciation, Depletion And Amortization	$6.000K	$5.000K
YoY Change	20.0%	66.67%
Cash From Operating Activities	-$1.910M	-$6.070M
YoY Change	-68.53%	-18.96%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$7.040M	-$250.0K
YoY Change	2716.0%
Cash From Investing Activities	-$8.290M	-$250.0K
YoY Change	3216.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$481.0K
YoY Change	-100.0%	-95.89%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	9.360M	-13.22M
YoY Change	-170.8%	-216.48%
NET CHANGE
Cash From Operating Activities	-1.910M	-6.070M
Cash From Investing Activities	-8.290M	-250.0K
Cash From Financing Activities	9.360M	-13.22M
Net Change In Cash	-840.0K	-19.54M
YoY Change	-95.7%	-606.22%
FREE CASH FLOW
Cash From Operating Activities	-$1.910M	-$6.070M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$1.910M	-$6.070M
YoY Change	-68.53%	-18.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	us-gaap	Assets Assets	89331000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	366000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	70000	USD
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	28000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3683000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4077000	USD
CY2014Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	14009000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	722000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	18808000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	46000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	212205000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-141728000	USD
CY2015Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px 0px 0px 24.45pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 24.45pt; FONT: 10pt Times New Roman, Times, Serif"> <b>Use of Estimates</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px 0px 0px 24.45pt; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 24.45pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company’s condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from our estimates. </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46819034	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46494034	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46819034	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46494034	shares
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	42000	USD
CY2014Q1	us-gaap	Depreciation Depreciation	5000	USD
CY2015Q1	us-gaap	Depreciation Depreciation	6000	USD
CY2015Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	376000	USD
CY2014Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	598000	USD
CY2015Q1	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	5000	USD
CY2014Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	38000	USD
CY2015Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	238000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	837000	USD
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	fbio	Percentage Of Tax Benefit Likely Of Being Realized PercentageOfTaxBenefitLikelyOfBeingRealized	0.5	pure
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2095000	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3490000	USD
CY2014Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2015Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	7439000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6582000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12071000	USD
CY2014Q1	fbio	Accretion And Interest Expenses AccretionAndInterestExpenses	966000	USD
CY2015Q1	fbio	Accretion And Interest Expenses AccretionAndInterestExpenses	331000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-7370000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-12056000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35900596	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38574702	shares
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9430425	shares
CY2015Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	94000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	94000	USD
CY2015Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	48000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	9361000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-19539000	USD
CY2015Q1	fbio	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	710000	USD
CY2014Q4	fbio	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	832000	USD
CY2015Q1	fbio	Other Short Term Liabilities Related To Manufacturing Rights OtherShortTermLiabilitiesRelatedToManufacturingRights	1500000	USD
CY2014Q4	fbio	Other Short Term Liabilities Related To Manufacturing Rights OtherShortTermLiabilitiesRelatedToManufacturingRights	1000000	USD
CY2015Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	244000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	213000	USD
CY2015Q1	fbio	Other Long Term Liabilities Related To Manufacturing Rights OtherLongTermLiabilitiesRelatedToManufacturingRights	0	USD
CY2014Q4	fbio	Other Long Term Liabilities Related To Manufacturing Rights OtherLongTermLiabilitiesRelatedToManufacturingRights	334000	USD
CY2014Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1135000	USD
CY2015Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1470000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2164365000	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2015Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	100000000	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2064365000	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1681032000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.69
CY2015Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2015Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.15
CY2015Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.82
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.58
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	170000	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	USD
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M17D
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y
CY2015Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	900000	USD
CY2015Q1	fbio	Employee Stock Purchase Plan Number Of Shares Purchased By Employees EmployeeStockPurchasePlanNumberOfSharesPurchasedByEmployees	63194	shares
CY2015Q1	fbio	Employee Stock Purchase Plan Number Of Shares Available For Future Sale EmployeeStockPurchasePlanNumberOfSharesAvailableForFutureSale	136806	shares
CY2014Q1	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	6000	USD
CY2015Q1	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	9000	USD
CY2015Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	15600000	USD
CY2015Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P6M
CY2014Q1	us-gaap	Profit Loss ProfitLoss	-7370000	USD
CY2015Q1	us-gaap	Profit Loss ProfitLoss	-12535000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1135000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1470000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-22000	USD
CY2014Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-84000	USD
CY2015Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-2000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-588000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1853000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6074000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8834000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-250000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1358000	USD
CY2014Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	32000	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	481000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-13215000	USD
CY2015Q1	us-gaap	Trading Securities TradingSecurities	20005000	USD
CY2014Q4	us-gaap	Trading Securities TradingSecurities	20002000	USD
CY2015Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	3945000	USD
CY2015Q1	us-gaap	Equity Method Investments EquityMethodInvestments	250000	USD
CY2014Q4	us-gaap	Equity Method Investments EquityMethodInvestments	250000	USD
CY2014Q4	us-gaap	Trading Securities Cost TradingSecuritiesCost	20002000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-831000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99521000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	79982000	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid	534000	USD
CY2015Q1	us-gaap	Interest Paid InterestPaid	80000	USD
CY2014Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4000	USD
CY2015Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1000	USD
CY2015Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	20005000	USD
CY2014Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	20002000	USD
CY2015Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	14586000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	14586000	USD
CY2015Q1	us-gaap	Long Term Investments LongTermInvestments	3945000	USD
CY2014Q4	us-gaap	Long Term Investments LongTermInvestments	4160000	USD
CY2014Q1	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	0	USD
CY2015Q1	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	-215000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-398000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	0	USD
CY2014Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	0	USD
CY2015Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	61000	USD
CY2014Q1	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	250000	USD
CY2015Q1	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	0	USD
CY2014Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	13655000	USD
CY2015Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2014Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	14009000	USD
CY2015Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2015Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	14600000	USD
CY2014Q1	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	400000	USD
CY2015Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-215000	USD
CY2014	us-gaap	Trading Securities Unrealized Holding Gain TradingSecuritiesUnrealizedHoldingGain	0	USD
CY2015Q1	us-gaap	Trading Securities Unrealized Holding Gain TradingSecuritiesUnrealizedHoldingGain	2000	USD
CY2014	us-gaap	Trading Securities Unrealized Holding Loss TradingSecuritiesUnrealizedHoldingLoss	0	USD
CY2015Q1	us-gaap	Trading Securities Unrealized Holding Loss TradingSecuritiesUnrealizedHoldingLoss	0	USD
CY2015Q1	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.256	pure
CY2015Q1	us-gaap	Share Price SharePrice	2.73
CY2015Q1	us-gaap	Investments In And Advances To Affiliates At Fair Value Period Increase Decrease InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease	200000	USD
CY2015Q1	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	3700000	USD
CY2014Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	515000	USD
CY2015Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	188000	USD
CY2014Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	14009000	USD
CY2015Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Receivable Current CapitalLeasesFutureMinimumPaymentsReceivableCurrent	500000	USD
CY2015Q1	fbio	Working Capital WorkingCapital	500000	USD
CY2014Q1	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	37000	USD
CY2015Q1	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	166000	USD
CY2015Q1	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	3945000	USD
CY2014Q4	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	4160000	USD
CY2015Q1	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	40000	USD
CY2014Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	1000000	USD
CY2015Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	300000	USD
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	4160000	USD
CY2015Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	0	USD
CY2015Q1	us-gaap	Marketable Securities MarketableSecurities	23950000	USD
CY2014Q4	us-gaap	Marketable Securities MarketableSecurities	24162000	USD
CY2015Q1	us-gaap	Trading Securities Cost TradingSecuritiesCost	20003000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1250000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	USD
CY2015Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	60153000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	70523000	USD
CY2015Q1	us-gaap	Minority Interest MinorityInterest	34000	USD
CY2014Q4	us-gaap	Minority Interest MinorityInterest	0	USD
CY2014Q1	us-gaap	Revenues Revenues	0	USD
CY2015Q1	us-gaap	Revenues Revenues	500000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	6582000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	12571000	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-788000	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-464000	USD
CY2014Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2015Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-479000	USD
CY2014Q1	us-gaap	Trading Securities Unrealized Holding Gain Loss TradingSecuritiesUnrealizedHoldingGainLoss	0	USD
CY2015Q1	us-gaap	Trading Securities Unrealized Holding Gain Loss TradingSecuritiesUnrealizedHoldingGainLoss	2000	USD
CY2014Q1	us-gaap	Trading Securities Realized Gain Loss TradingSecuritiesRealizedGainLoss	0	USD
CY2015Q1	us-gaap	Trading Securities Realized Gain Loss TradingSecuritiesRealizedGainLoss	1000	USD
CY2014Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2015Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1250000	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2015Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	216000	USD
CY2014Q1	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	0	USD
CY2015Q1	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	10000000	USD
CY2014Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2015Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	108000	USD
CY2014Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2015Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	855000	USD
CY2015Q1	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	-513000	USD
CY2015Q1	fbio	Working Capital Committed WorkingCapitalCommitted	100000	USD
CY2014Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2015Q1	us-gaap	Stock Issued1 StockIssued1	-513000	USD
CY2014Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	723000	USD
CY2015Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2015Q1	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	2000000	USD
CY2014Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	0	USD
CY2015Q1	fbio	Lease Abandonment Current LeaseAbandonmentCurrent	165000	USD
CY2014Q4	fbio	Lease Abandonment Current LeaseAbandonmentCurrent	165000	USD
CY2015Q1	fbio	Lease Abandonment Non Current LeaseAbandonmentNonCurrent	207000	USD
CY2014Q4	fbio	Lease Abandonment Non Current LeaseAbandonmentNonCurrent	268000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	USD
CY2015Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-500000	USD

Files In Submission

Name	View Source	Status
0001144204-15-029340-index-headers.html	Edgar Link	pending
0001144204-15-029340-index.html	Edgar Link	pending
0001144204-15-029340.txt	Edgar Link	pending
0001144204-15-029340-xbrl.zip	Edgar Link	pending
fbio-20150331.xml	Edgar Link	completed
fbio-20150331.xsd	Edgar Link	pending
fbio-20150331_cal.xml	Edgar Link	unprocessable
fbio-20150331_def.xml	Edgar Link	unprocessable
fbio-20150331_lab.xml	Edgar Link	unprocessable
fbio-20150331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v409020_10q.htm	Edgar Link	pending
v409020_ex31-1.htm	Edgar Link	pending
v409020_ex31-2.htm	Edgar Link	pending
v409020_ex32-1.htm	Edgar Link	pending
v409020_ex32-2.htm	Edgar Link	pending
v409020_ex99-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBIO
Fortress Biotech, Inc. Stock $fbio

2015 Q1 Form 10-Q Financial Statement

#000114420415029340 Filed on May 11, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO Fortress Biotech, Inc. Stock $fbio

2015 Q1 Form 10-Q Financial Statement

#000114420415029340 Filed on May 11, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO
Fortress Biotech, Inc. Stock $fbio